Pfizer's Ibrance conquers new breast cancer territory
This article was originally published in Scrip
Executive Summary
Pfizer's new CDK4 and 6 inhibitor Ibrance (palbociclib) has hit its progression-free survival primary endpoint in the Phase III PALOMA-3 study in a new breast cancer population, stopping the trial early.
You may also be interested in...
Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio
Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.
Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.
Five Late-Breaking Studies To Look Out For At ASCO
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.